These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29718730)

  • 1. Investigational drugs for hyperuricemia, an update on recent developments.
    Pascart T; Richette P
    Expert Opin Investig Drugs; 2018 May; 27(5):437-444. PubMed ID: 29718730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert opinion on emerging urate-lowering therapies.
    Stamp LK; Merriman TR; Singh JA
    Expert Opin Emerg Drugs; 2018 Sep; 23(3):201-209. PubMed ID: 30244605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational drugs for hyperuricemia.
    Shahid H; Singh JA
    Expert Opin Investig Drugs; 2015; 24(8):1013-30. PubMed ID: 26073200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New medications in development for the treatment of hyperuricemia of gout.
    Diaz-Torné C; Perez-Herrero N; Perez-Ruiz F
    Curr Opin Rheumatol; 2015 Mar; 27(2):164-9. PubMed ID: 25603039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent approaches to gout drug discovery: an update.
    Otani N; Ouchi M; Kudo H; Tsuruoka S; Hisatome I; Anzai N
    Expert Opin Drug Discov; 2020 Aug; 15(8):943-954. PubMed ID: 32329387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future therapies for gout.
    Pascart T; Richette P
    Expert Opin Pharmacother; 2017 Aug; 18(12):1201-1211. PubMed ID: 28689430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of available urate-lowering drugs: a critical review.
    Strilchuk L; Fogacci F; Cicero AF
    Expert Opin Drug Saf; 2019 Apr; 18(4):261-271. PubMed ID: 30915866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.
    Steinberg AS; Vince BD; Choi YJ; Martin RL; McWherter CA; Boudes PF
    J Rheumatol; 2017 Mar; 44(3):374-379. PubMed ID: 27980008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study.
    Hosoya T; Sasaki T; Hashimoto H; Sakamoto R; Ohashi T
    J Clin Pharm Ther; 2016 Jun; 41(3):298-305. PubMed ID: 27079434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2 as a therapeutic target candidate for gout.
    Fujita K; Ichida K
    Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging uricosurics for gout.
    Terkeltaub R
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):247-249. PubMed ID: 27937050
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials.
    Fitz-Patrick D; Roberson K; Niwa K; Fujimura T; Mori K; Hall J; Yan X; Shen Z; Liu S; Ito Y; Baumgartner S
    Mod Rheumatol; 2019 Nov; 29(6):1042-1052. PubMed ID: 30334639
    [No Abstract]   [Full Text] [Related]  

  • 14. Gout and hyperuricemia.
    Chilappa CS; Aronow WS; Shapiro D; Sperber K; Patel U; Ash JY
    Compr Ther; 2010; 36():3-13. PubMed ID: 21229813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
    J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan.
    Yu KH; Chen DY; Chen JH; Chen SY; Chen SM; Cheng TT; Hsieh SC; Hsieh TY; Hsu PF; Kuo CF; Kuo MC; Lam HC; Lee IT; Liang TH; Lin HY; Lin SC; Tsai WP; Tsay GJ; Wei JC; Yang CH; Tsai WC
    Int J Rheum Dis; 2018 Apr; 21(4):772-787. PubMed ID: 29363262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel uricosurics.
    Bardin T; Richette P
    Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i42-i46. PubMed ID: 29272511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study.
    Hosoya T; Sasaki T; Ohashi T
    Clin Rheumatol; 2017 Mar; 36(3):649-656. PubMed ID: 27832384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
    Ishikawa T; Takahashi T; Taniguchi T; Hosoya T
    Expert Opin Pharmacother; 2021 Aug; 22(11):1397-1406. PubMed ID: 33926357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.